Pfizer acquires antibody optimization company

Pfizer announced yesterday that it has agreed to acquire the privately held antibody optimization company Bioren. Financial terms of the deal were not disclosed.
"The acquisition of Bioren strengthens Pfizer's commitment to the antibody space," said Nick Saccomano, Pfizer senior vice president for worldwide research technology, in a statement. "The ability to use and develop these technologies will help Pfizer identify new antibody leads as well as improve current antibodies in development."
Bioren is based in San Carlos, Calif.
You must be a registered member of MMM to post a comment.

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.